EUCTR2019-004066-18-GB
Active, not recruiting
Phase 1
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Frontotemporal Dementia
- Sponsor
- Alector Inc.
- Enrollment
- 180
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Each participant must meet all of the following criteria to be enrolled in this study.
- •Key Inclusion Criteria:
- •Known progranulin genetic mutation causing FTD.
- •CDR plus NACC\-FTLD score 0\-2\.
- •If symptomatic, one of the criteria for the diagnosis of probable behavioral variant FTD or FTD\-semantic subtype or FTD\-Progressive Nonfluent Aphasia.
- •Study partner who consents to study participation and who cares for/visits the patient daily for at least 5 hours per week.
- •Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from their legal decision maker).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •Dementia due to a condition other than FTD including, but not limited to, Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, Huntington disease, or vascular dementia.
- •Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
- •Current uncontrolled hypertension, diabetes mellitus or thyroid disease.
- •Clinically significant heart disease, liver disease or kidney disease.
- •History or evidence of clinically significant brain disease other than FTD.
- •Females who are pregnant or breastfeeding, or planning to conceive within the study period.
- •Any experimental vaccine or gene therapy.
- •History of cancer except:
- •If considered to be cured
- •If not being actively treated with anti\-cancer therapy or radiotherapy and, in the opinion of the investigator, not likely to require treatment in the ensuing 3 years
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD.Frontotemporal Dementia.MedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-004066-18-ITAlector Inc.180
Active, not recruiting
Phase 1
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTD followed by An Open-Label Study to Evaluate Long-Term Safety and Tolerability of AL001 in FTD.Frontotemporal DementiaMedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-004066-18-DEAlector Inc.110
Active, not recruiting
Not Applicable
A Study in Patients With Rheumatoid Arthritis(FLEX-V)Rheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2010-022207-22-PLEli Lilly and Company555
Active, not recruiting
Phase 1
A Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AL001 in FTDFrontotemporal DementiaMedDRA version: 21.1Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2019-004066-18-NLAlector Inc.180
Active, not recruiting
Not Applicable
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of LY2127399 in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response to one or more TNF-a InhibitorsRheumatoid ArthritisMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2010-022207-22-GREli Lilly and Company555